XOMA Royalty Beheer

Beheer criteriumcontroles 2/4

De CEO XOMA Royalty is Owen Hughes, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.48M, bestaande uit 5% salaris en 95% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 1.05M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 5.8 jaar.

Belangrijke informatie

Owen Hughes

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris	5.0%
Dienstverband CEO	1.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Aug 14

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

May 11

XOMA EPS misses by $0.55, misses on revenue

May 06

XOMA gets milestone payment from Janssen Biotech

May 03

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Mar 17

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Dec 01

Analyse CEO-vergoeding

Hoe is Owen Hughes's beloning veranderd ten opzichte van XOMA Royalty's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$35m
Jun 30 2024	n/a	n/a	-US$24m
Mar 31 2024	n/a	n/a	-US$42m
Dec 31 2023	US$2m	US$125k	-US$46m

Compensatie versus markt: De totale vergoeding ($USD 2.48M ) Owen } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.18M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Owen te vergelijken met de prestaties van het bedrijf.

CEO

Owen Hughes (49 yo)

1.8yrs

Tenure

US$2,482,735

Compensatie

Mr. Owen P. Hughes, Jr. serves as Chief Executive Officer of XOMA Royalty Corporation (formerly known as XOMA Corporation) from January 2024 and serves as its Director since January 01, 2023 and served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Owen Hughes	CEO & Director	1.8yrs	US$2.48m	0.30% $ 1.1m
Thomas Burns	Senior VP of Finance & CFO	9.6yrs	US$2.27m	0.12% $ 437.6k
Brad Sitko	Chief Investment Officer	1.8yrs	US$8.56m	0.060% $ 213.5k

1.8yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van XOMA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Owen Hughes	CEO & Director	1.8yrs	US$2.48m	0.30% $ 1.1m
Jack Wyszomierski	Independent Chairman	14.3yrs	US$232.53k	0.055% $ 194.3k
Joseph Limber	Independent Director	11.9yrs	US$210.04k	0.053% $ 186.7k
Matthew Perry	Independent Director	7.8yrs	US$197.54k	0.10% $ 354.8k
Barbara Kosacz	Independent Director	5.8yrs	US$196.04k	0% $ 0
Heather Franklin	Independent Director	3.3yrs	US$203.95k	0% $ 0
Natasha Hernday	Independent Director	4.3yrs	US$207.64k	0% $ 0

5.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van XOMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

XOMA Royalty Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

XOMA Corporation, Annual General Meeting, May 15, 2024

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

XOMA Corporation, Annual General Meeting, May 18, 2022

CEO & Director recently sold US$303k worth of stock

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Consensus revenue estimates increase by 64%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech